Document:

exv4w2

EXHIBIT 4.2

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

          THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made and
entered into as of                      ___, 2010, by and among REVA Medical, Inc., a Delaware corporation
(the “Company”), and each of the individuals or entities whose names are set forth on
Schedule A hereto (each, an “Investor” and collectively, the “Investors”).

RECITALS:

          WHEREAS, the Company (through its predecessor in interest) and the Investors have previously
entered into an Amended and Restated Investors’ Rights Agreement dated as of December 7, 2007 (the
“Prior Agreement”), pursuant to which such holders are currently entitled to certain
investor rights and bound by certain covenants and restrictions.

          WHEREAS, the Company and the Investors desire to enter into this Agreement in order to amend,
restate and replace their rights and obligations under the Prior Agreement with the rights and
obligations set forth in this Agreement, effective upon a Qualified Initial Public Offering (as
defined below).

          WHEREAS, pursuant to the terms of a certain Securities Purchase Agreement dated December 7,
2007, by and among the Company and the Investors (as amended, restated, supplemented or otherwise
modified from time to time, the “Purchase Agreement”), the Company issued to the Investors
(i) shares (the “Series H Preferred Shares”) of a newly created series of the Company’s
preferred stock designated as “Series H Convertible Preferred Stock” (the “Series H Preferred
Stock”), and (ii) warrants (the “Warrants”), to acquire up to that number of additional
shares of Common Stock equal to 20% of the number of shares of Common Stock initially issuable upon
conversion of the Series H Preferred Shares issued to each such Investor (the shares of Common
Stock issuable upon exercise of or otherwise pursuant to the Warrants, collectively, the
“Warrant Shares”).

          WHEREAS, the Prior Agreement may be amended by agreement of the Company, the Requisite
Investors (as defined below), and Holders (as defined below) holding at least a majority of the
issued and outstanding Common Stock (on an as-converted basis) then held by all Holders.

          WHEREAS, the Company has executed this Agreement, and the Investors who are signatories to
this Agreement hold at least that number of shares necessary to amend and restate the Prior
Agreement.

          NOW, THEREFORE, in consideration of the foregoing and the mutual promises and covenants set
forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Investors hereby agree that, effective upon a
Qualified Initial Public Offering (as defined below), the Prior Agreement is superseded and
replaced in its entirety by this Agreement, including with respect to those Investors who are not
signatories to this Agreement, and the parties hereto further agree as follows:

-1-

 

Article I Definitions.

          1.1 General Definitions. All capitalized terms not otherwise defined in this
Agreement shall have the meanings ascribed thereto in the Purchase Agreement. As used in this
Agreement, unless the context otherwise requires, the following terms shall have the respective
meanings set forth below:

          “Affiliate” means, with respect to any Person, any other Person directly or indirectly
controlling or controlled by or under direct or indirect common control with such specified Person.
For the purposes of this definition, “control,” when used with respect to any Person, means the
power to direct the management and policies of such Person, directly or indirectly, whether through
the ownership of voting securities, by contract or otherwise; and the terms “affiliated,”
“controlling” and “controlled” have meanings correlative to the foregoing.

          “Agreement” shall have the meaning ascribed to it in the preamble to this Agreement.

          “Availability Date” shall have the meaning ascribed to it in Section 2.4(m).

          “Board” means the Board of Directors of the Company.

          “Certificate of Incorporation” means the Amended and Restated Certificate of
Incorporation of the Company which sets forth the rights, preferences and privileges of the
Preferred Stock.

          “Commission” means the U.S. Securities and Exchange Commission or any other federal
agency then administering the Securities Act and other federal securities laws.

          “Common Stock” shall have meaning ascribed to it in the recitals to this Agreement.

          “Company” shall have the meaning ascribed to it in the preamble to this Agreement.

          “Demand Registration” shall have the meaning ascribed to it in Section 2.1(a).

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

          “Holders” means any holders of Registrable Securities.

          “Indemnified Person” shall have the meaning ascribed to it in Section 2.7(c).

          “Indemnifying Party” shall have the meaning ascribed to it in Section 2.7(c).

          “Initial Public Offering” means the first underwritten public offering of the Common
Stock by the Company pursuant to an effective Registration Statement.

-2-

 

          “Initiating Holders” shall have the meaning ascribed to it in Section 2.1(a).

          “Investor(s)” shall have the meaning ascribed to it in the preamble to this Agreement.

          “Lead Investor” shall mean, collectively, Cerberus Partners, L.P., Cerberus
International, Ltd., Cerberus Series Four Holdings, LLC, Cerberus America Series Two Holdings, LLC
and Gabriel Assets, LLC.

          “Losses” shall have the meaning ascribed to it in Section 2.7(a).

          “Major Investor” means each of the Investors holding a minimum of 500,000 shares of
Registrable Securities.

          “Other Stockholders” shall have the meaning ascribed to it in Section 2.1(d).

          “Piggy-Back Notice” shall have the meaning ascribed to it in Section 2.2(a).

          “Preferred Stock” means the Prior Preferred Stock and the Series H Preferred Stock.

          “Prior Agreement” shall have the meaning ascribed to it in the recitals to this
Agreement.

          “Prior Preferred Stock” means the Company’s Series A Preferred Stock, Series B
Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock,
Series F Preferred Stock, Series G-1 Preferred Stock, and Series G-2 Preferred Stock.

          “Prospectus” shall mean the prospectus included in any Registration Statement, as
amended or supplemented by any prospectus supplement, with respect to the terms of the offering of
any portion of the Registrable Securities covered by such Registration Statement and by all other
amendments and supplements to the prospectus, including post-effective amendments and all material
incorporated by reference in such prospectus.

          “Purchase Agreement” shall have the meaning ascribed to it in the recitals to this
Agreement.

          “Qualified Initial Public Offering” means any initial public offering of securities by
the Company pursuant to an effective Registration Statement covering the sale of such securities,
pursuant to which the Company shall actually receive aggregate net cash proceeds (not subject to
any contingencies) equal to no less than $50,000,000.

          “Register,” “registered” and “registration” refer to a registration
made by preparing and filing a Registration Statement or similar document in compliance with the
Securities Act, and the declaration or ordering of effectiveness of such Registration Statement or
document.

-3-

 

          “Registrable Securities” means: (i) the shares of Preferred Stock; (ii) any and all
shares of Common Stock issued or issuable in respect of the Preferred Stock upon any stock split,
reverse stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale
of assets or similar event; (iii) the shares of Common Stock issuable as payment-in-kind dividends
on the Series H Preferred Stock in accordance with the terms of the Certificate of Incorporation;
(iv) the Warrant Shares; and (v) any other shares of Common Stock acquired by the Investors at any
time. Notwithstanding the foregoing, the term “Registrable Securities” shall not include any
shares which have been (i) sold to or through a broker or dealer or underwriter in a public
distribution or a public securities transaction, (ii) sold in a transaction exempt from the
registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof
so that all transfer restrictions and restrictive legends with respect thereto are removed upon the
consummation of such sale, (iii) registered under the Securities Act pursuant to an effective
Registration Statement filed thereunder or (iv) publicly sold pursuant to Rule 144 under the
Securities Act.

          “Registration Statement” means a Registration Statement filed by the Company with the
Commission for a public offering and sale of securities of the Company (other than a Registration
Statement on Form S-8 or Form S-4, or their successors, or any other form for a similar limited
purpose, or any Registration Statement covering only securities proposed to be issued in exchange
for securities or assets of another corporation).

          “Requisite Investors” means the Lead Investor (so long as the Lead Investor holds, in
the aggregate, at least 50% of the shares of Common Stock issued and/or issuable upon conversion of
the Series H Preferred Shares it acquires pursuant to the Purchase Agreement) and a majority of the
Investors (excluding, for purposes of calculating such majority, the Lead Investor, so long as the
Lead Investor holds, in the aggregate, at least 50% of the shares of Common Stock issued and/or
issuable upon conversion of the Series H Preferred Shares it acquires pursuant to the Purchase
Agreement).

          “Securities Act” means the Securities Act of 1933, as amended, or any successor
federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

          “Series H Preferred Shares” shall have the meaning ascribed to it in the recitals to
this Agreement.

          “Series H Preferred Stock” shall have the meaning ascribed to it in the recitals to
this Agreement.

          “Warrants” shall have the meaning ascribed to it in the recitals to this Agreement.

          “Warrant Shares” shall have the meaning ascribed to it in the recitals to this
Agreement.

-4-

 

Article II  Registration Rights; Restrictions on Transfer.

          2.1 Demand Registration.

               (a) At any time after the closing of an Initial Public Offering (but not within six (6) months
of the effective date of a Registration Statement of the Company) or the seventh (7th)
anniversary of the Closing, whichever occurs first, the Requisite Investors may require that the
Company register for sale under the Securities Act all or any portion of the Registrable Securities
held by such Investors (the “Initiating Holders”) for sale in the manner specified in such
notice; provided, that (i) the portion of the Registrable Securities required to be so
registered equals at least 100% of the shares of Common Stock issuable upon conversion of the
shares of Series H Preferred Stock then outstanding or (ii) such offering is expected to exceed
$10,000,000 in the aggregate, counting all other securities of the Company being included in such
offering (a “Demand Registration”).

               (b) Following receipt of any notice under Section 2.1, the Company shall (i) within
ten (10) days of the receipt thereof, give written notice to all Holders (the “Registration
Notice”) and (ii) use its best efforts to effect the registration under the Securities Act as
soon as practicable, and in any event within one hundred eighty (180) days after receipt of such
notice, for public sale in accordance with the method of disposition specified in such notice of
the number of Registrable Securities which the Holders request to be registered, subject to the
limitations of Section 2.1(d), within twenty (20) days following delivery of the
Registration Notice by the Company in accordance with Section 3.6.

               (c) If the Initiating Holders intend to distribute the Registrable Securities covered by their
notice by means of an underwriting, the Initiating Holders shall so advise the Company as a part of
their demand made pursuant to this Section 2.1. If the method of disposition is an
underwritten public offering, the Initiating Holders may designate the managing underwriter of such
offering, which designation shall be subject to the Company’s approval, not to be unreasonably
withheld. Each Holder may elect to include in such underwriting all or any part of the Registrable
Securities it holds, subject to the limitations provided for in Section 2.1(d).

               (d) A Registration Statement filed pursuant to this Section 2.1 may, subject to the
following provisions and in addition to the Registrable Securities held by Holders, include shares
of Common Stock for sale by the Company for its own account for sale in accordance with the method
of disposition specified by the Initiating Holders. If such registration shall be underwritten,
the Company and all Holders proposing to distribute their shares through such underwriting shall
enter into an underwriting agreement in customary form with the representative of the underwriter
or underwriters selected for such underwriting. If and to the extent that the managing underwriter
determines that marketing factors require a limitation on the number of shares to be included in
such registration, then the shares of Common Stock sought to be registered by Holders who are not
Investors (collectively, the “Other Stockholders”) and shares of Common Stock to be sold by
the Company for its own account shall be excluded from such registration to the extent so required
by such managing underwriter, and unless the Other Stockholders and the Company have otherwise
agreed in writing, such exclusion shall be applied first to the shares of Common Stock of the
Company to be included for its own account to the extent required by the managing underwriter and
then to the shares sought to be registered by the Other Stockholders to the extent required by the
managing underwriter. If, after exclusion of all shares sought to be registered by the Company and
the Other Stockholders, the managing underwriter further determines that marketing factors require
a limitation on the number of

-5-

 

Registrable Securities to be registered under this Section 2.1, then Registrable
Securities held by Investors shall be excluded in accordance with Section 2.5 to the extent
so required by the managing underwriter. In any event, all securities to be sold other than
Registrable Securities shall be excluded prior to any exclusion of Registrable Securities. No
Registrable Securities or other securities, in either case, excluded from the underwriting by
reason of the underwriter’s marketing limitation shall be included in such registration. If any of
the Holders who have requested inclusion in such registration as provided above, disapproves of the
terms of the underwriting, then such Holders may elect to withdraw therefrom by written notice to
the Company and the managing underwriter. The securities so withdrawn shall also be withdrawn from
registration. The Company shall not include, and shall not permit other holders of its securities
to include, any securities in such Demand Registration other than securities of the same class or
series as the Registrable Securities to which the demand has been made pursuant to Section
2.1.

               (e) Notwithstanding the foregoing, if the Company shall furnish to the Holders requesting a
Registration Statement pursuant to this Section 2.1, a certificate signed by the Chief
Executive Officer of the Company stating that in the good faith judgment of the Board, it would be
seriously detrimental to the Company and its stockholders for such Registration Statement to be
filed and it is therefore essential to defer the filing of such Registration Statement, the Company
shall have the right to defer taking action with respect to such filing for a period of not more
than ninety (90) days after receipt of the request of the Initiating Holders; provided, however,
that the Company may not utilize this right more than once in any twelve-month period.

               (f) In addition, the Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to this Section 2.1:

               (i) After the Company has effected two registrations pursuant to this Section 2.1
which cover all the Registrable Securities sought to be included in such registrations and such
registrations have been declared or ordered effective; or

               (ii) During the period starting with the date sixty (60) days prior to the Company’s good
faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after
the effective date of, a registration subject to Section 2.2 hereof; provided that the
Company is actively employing in good faith all reasonable efforts to cause such registration
statement to become effective; or

               (iii) If the Initiating Holders propose to dispose of shares of Registrable Securities that
may be immediately registered on Form S-3 pursuant to a request made pursuant to Section
2.3 below.

          2.2 Piggy-Back Registration.

               (a) If the Company at any time (other than pursuant to Section 2.1 or Section
2.3) proposes to register any of its securities under the Securities Act for sale to the
public, whether for its own account or for the account of other stockholders of the Company or both
(except with respect to (i) an Initial Public Offering, (ii) Registration Statements on Forms

-6-

 

S-4, S-8 or any successor to such forms, or (iii) any Registration Statement including only
securities issued pursuant to a dividend reinvestment plan), each such time the Company shall
promptly give written notice to the holders of Registrable Securities of its intention to do so
(the “Piggy-Back Notice”). Upon the written request of a majority of the Holders (which
majority must include the Lead Investor, so long as the Lead Investor holds at least 50% of the
Series H Preferred Shares acquired by it pursuant to the Purchase Agreement), received by the
Company within twenty (20) days after the delivery of such Piggy-Back Notice by the Company in
accordance with Section 3.6, to register any or all of the Registrable Securities, the
Company shall use its best efforts to cause the Registrable Securities as to which registration
shall have been so requested to be included in such Registration Statement. If the Registration
Statement relates to an underwritten public offering, the Company shall so advise the holders of
Registrable Securities as a part of a Piggy-Back Notice. In such event, each Holder’s right to
include Registrable Securities in such registration shall be conditioned upon its participation in
such underwriting to the extent provided herein. The Holders, if participating in such
distribution, shall enter into an underwriting agreement in customary form with the underwriter or
underwriters selected for underwriting by the Company.

               (b) Any request by a Holder for inclusion in any registration may be withdrawn, in whole or in
part, at any time prior to the effective date of the Registration Statement for such offering.

               (c) The Company shall have the right to terminate or withdraw any registration contemplated
under this Section 2.2 prior to the effectiveness of such registration, whether or not the
Holders have elected to include securities in such registration. The expenses of such registration
shall be borne by the Company, in accordance with Section 2.6 hereof.

               (d) There shall be no limitation on the number of registrations a Holder may participate in
under this Section 2.2.

          2.3 Registration on Form S-3. If at any time (i) Holders of at least thirty percent
(30%) of the Registrable Securities then outstanding request that the Company file a Registration
Statement on Form S-3 or any comparable or successor form thereto for a public offering of all or
any portion of the of Registrable Securities and (ii) the Company is a registrant entitled to use
Form S-3 or any successor form thereto to effect the distribution of such Registrable Securities
for public sale or resale (as the case may be), then the Company shall promptly give written notice
of the proposed registration to all other Holders and shall use its best efforts to register under
the Securities Act on Form S-3 or any comparable or successor form thereto, for public sale or
resale (as the case may be) in accordance with the method of disposition specified in such notice,
the number of Registrable Securities specified in such notice, together with the number of
Registrable Securities requested by any other Holder or Holders for inclusion in such registration,
received by the Company within fifteen (15) days after delivery of such notice by the Company.
Whenever the Company is required by this Section 2.3 to use its best efforts to effect the
registration of Registrable Securities, each of the procedures and requirements of Section
2.1 shall apply to such registration. Notwithstanding the foregoing, the Company shall not be
obligated to effect any such registration pursuant to this Section 2.3: (1) if Form S-3 is
not available for such offering by the Holders; (2) if the Holders, together with the holders of
any other securities of the Company entitled to inclusion in such registration, propose to sell

-7-

 

Registrable Securities and such other securities (if any) at an aggregate price to the public
(net of any underwriters’ discounts or commissions) of less than $2,500,000; or (3) if the Company
shall furnish to the Holders a certificate signed by the President of the Company stating that in
the good faith judgment of the Board, it would be materially detrimental to the Company and its
stockholders for such Form S-3 registration to be effected at such time, in which event the Company
shall have the right to defer the filing of the Form S-3 registration statement for a period of not
more than sixty (60) days after receipt of the request of the Holder or Holders under this
Section 2.3; provided, however, that the Company shall not utilize this right more than
once in any twelve month period; (4) if the Company has already effected two registrations on Form
S-3 for the Holders pursuant to this Section 2.3 within the immediately preceding 12 month
period; or (5) in any particular jurisdiction in which the Company would be required to qualify to
do business or to execute a general consent to service of process in effecting such registration,
qualification or compliance. Subject to the foregoing, there shall be no limitation on the number
of registrations on Form S-3 which may be requested and obtained under this Section 2.3.

          2.4 Registration Procedures. If and whenever the Company is required by the
provisions of Sections 2.1, 2.2 or 2.3 to use its best efforts to effect the registration
of any Registrable Securities under the Securities Act, the Company shall, as expeditiously as
possible:

               (a) Prepare and file with the Commission a Registration Statement on the applicable form with
respect to such securities and use its best efforts to cause such Registration Statement to become
and remain effective until the earlier of (i) the sale of all of the Registrable Securities covered
thereby and (ii) two years following the commencement of the offering thereunder; provided,
however, that in the case of any registration of Registrable Securities on Form S-3 or on a
comparable or successor form which are intended to be offered on a continuous or delayed basis,
such two year period shall be extended, if necessary, until all such Registrable Securities are
sold, provided that Rule 415 or any successor rule under the Securities Act permits an
offering on a continuous or delayed basis; and provided, further, that, as soon as
practicable but in no event later than five (5) Business Days before filing such Registration
Statement, any related prospectus or any amendment or supplement thereto (other than any amendment
or supplement made solely as a result of incorporation by reference of documents filed with the
Commission subsequent to the filing of such Registration Statement), the Company shall furnish to
(x) the Lead Investor for so long as the Lead Investor continues to hold 5% or more of the
outstanding Registrable Securities or is an Affiliate of a director of the Company and (y) the
underwriters, if any, copies of all such documents proposed to be filed, which documents shall be
subject to review by the Lead Investor and any such underwriters;

               (b) Prepare and file with the Commission such amendments and supplements to such Registration
Statement and the prospectus used in connection therewith as may be necessary to keep such
Registration Statement effective for the period specified herein and comply with the provisions of
the Securities Act with respect to the disposition of all Registrable Securities covered by such
Registration Statement in accordance with the sellers’ intended method of disposition set forth in
such Registration Statement for such period; provided, that the Company shall comply with
the provisions of Section 2.4(a) above;

               (c) Furnish to the Holders and to each underwriter copies of the Registration Statement and
each such amendment and supplement thereto (together with all

-8-

 

exhibits thereto) and the prospectus included therein and any other prospectus filed under
Rule 424 or Rule 434 under the Securities Act as the Holders and such underwriter reasonably may
request in order to facilitate the disposition of the Registrable Securities covered by such
Registration Statement;

               (d) Use its best efforts to register or qualify the Registrable Securities covered by such
Registration Statement under the securities or “blue sky” laws of such jurisdictions as the sellers
of the Registrable Securities or, in the case of an underwritten public offering, the managing
underwriter reasonably shall request; provided, however, that the Company shall not
be required to (i) qualify to transact business as a foreign corporation in any jurisdiction where
it is not so qualified, (ii) consent to general service of process or (iii) submit to taxation in
any such jurisdiction, unless the Company is already subject to service or subject to taxation in
such jurisdiction;

               (e) Use its best efforts to list or qualify the Registrable Securities covered by such
Registration Statement on any securities exchange or quotation system on which the Common Stock is
then listed;

               (f) Comply in all material respects with all applicable rules and regulations under the
Securities Act and Exchange Act;

               (g) Immediately notify the Holders and each underwriter under such Registration Statement, at
any time when a prospectus relating thereto is required to be delivered under the Securities Act,
of the happening of any event which has resulted or would result in the prospectus contained in
such Registration Statement, as then in effect, to include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading, and promptly
prepare and furnish to such seller and underwriter an updated prospectus;

               (h) If the offering is underwritten, and at each Holder’s request, use its best efforts to
furnish on the date that Registrable Securities are delivered to the underwriters for sale pursuant
to such registration (i) an opinion, dated such date, of counsel to the Company, addressed to the
underwriters and the Holders to such effect as reasonably may be requested by the underwriters, and
(ii) a letter, dated such date, from the independent public accountants retained by the Company,
addressed to the underwriters and, if applicable, the Holders requesting registration of
Registrable Securities, in form and substance as is customarily given by independent public
accountants to underwriters in an underwritten public offering, and deliver copies of such letter
to such Holders;

               (i) Upon reasonable notice and at reasonable times during normal business hours, make
available for inspection by (x) the Lead Investor for so long as the Lead Investor continues to
hold 5% or more of the outstanding Registrable Securities or is an Affiliate of a director of the
Company and (y) any underwriter participating in any distribution pursuant to such Registration
Statement, and any attorney, accountant or other agent retained by such Holders or such
underwriter, reasonable access to all financial and other records, pertinent corporate documents
and properties of the Company, as such parties may reasonably request, and

-9-

 

cause the Company’s officers, directors and employees to supply all information reasonably
requested by any of the Holders, such underwriter, attorney, accountant or agent in connection with
such Registration Statement;

               (j) Notify the Holders (i) when the prospectus or any prospectus supplement or post-effective
amendment has been filed, and, with respect to such Registration Statement or any post-effective
amendment, when the same has become effective, (ii) of any request by the Commission for amendments
or supplements to such Registration Statement or to amend or supplement such prospectus or for
additional information, (iii) of the issuance by the Commission of any stop order suspending the
effectiveness of such Registration Statement or the initiation of any proceeding for that purpose
and (iv) of the suspension of the qualification of securities covered by such registration for
offering or sale in any jurisdiction, or of the initiation of any proceeding for any of such
purposes;

               (k) Take such other actions as the Holders or the underwriters reasonably request in order to
expedite or facilitate the disposition of the Registrable Securities, including, without
limitation, preparing for, and participating in, such number of “road shows” and all such other
customary selling efforts as the underwriters reasonably request in order to expedite or facilitate
such disposition;

               (l) Use its reasonable best efforts to prevent the issuance of any stop order or other
suspension of effectiveness and, if such order is issued, obtain the withdrawal of any such order
as soon as reasonably possible; and

               (m) Otherwise use its reasonable best efforts to comply with all applicable rules and
regulations of the Commission under the Securities Act and the Exchange Act and take such other
actions as may be reasonably necessary to facilitate the registration of the Registrable Securities
hereunder; and make available to its security holders, as soon as reasonably practicable, but not
later than the Availability Date (as defined below), an earnings statement covering a period of at
least twelve (12) months, beginning after the effective date of each Registration Statement, which
earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act (for the
purpose of this Section 2.4(m), “Availability Date” means the forty-fifth
(45th) day following the end of the fourth fiscal quarter that includes the effective
date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter
of the Company’s fiscal year, “Availability Date” means the ninetieth (90th) day
after the end of such fourth fiscal quarter).

          2.5 Underwriting Requirements. In connection with any offering involving an
underwriting of shares of the Company’s capital stock, the Company shall not be required to include
any of the Registrable Securities in such underwriting unless the Holders accept the terms of the
underwriting as agreed upon between the Company and its underwriters, and then only in such
quantity as the underwriters in their sole discretion determine will not jeopardize the success of
the offering by the Company. If the total number of securities, including Registrable Securities,
requested by stockholders to be included in such offering exceeds the number of securities to be
sold (other than by the Company) that the underwriters in their reasonable discretion determine is
compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable

-10-

 

Securities, which the underwriters and the Company in their sole discretion determine will not
jeopardize the success of the offering. If the underwriters determine that less than all of the
Registrable Securities requested to be registered can be included in such offering, then the
Registrable Securities that are included in such offering shall be allocated among the selling
Holders in proportion (as nearly as practicable) to the number of Registrable Securities owned by
each selling Holder or in such other proportions as shall mutually be agreed to by all such selling
Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities
held by Investors included in the offering be reduced unless all other securities (including
Registrable Securities held by Other Stockholders) are first entirely excluded from the offering,
and (ii), subject to the immediately preceding clause (i), the number of Registrable Securities
held by Other Stockholders included in the offering be reduced unless all other securities
(excluding, for the avoidance of doubt, the Registrable Securities held by the Investors and any
securities held by the Company) are first entirely reduced to zero.

          2.6 Expenses. The Company shall bear all reasonable expenses incurred in complying
with Sections 2.1, 2.2, 2.3 and 2.4, including, without limitation, all registration and
filing fees (exclusive of underwriting discounts and commissions attributable to the Registrable
Securities being registered pursuant to the exercise of demand rights in accordance with
Section 2.1 and fees of legal counsel other than one counsel for all selling Holders to be
selected by the Lead Investor, printing expenses, fees and disbursements of counsel and independent
public accountants for the Company, fees and expenses (including counsel fees) incurred in
connection with complying with state securities or “blue sky” laws, reasonable fees and
disbursements of transfer agents and registrars and costs of any insurance which might be obtained
by the Company with respect to the offering by the Company.

          2.7 Indemnification and Contribution.

               (a) The Company shall indemnify and hold harmless, each Holder and its Affiliates and the
directors, officers, employees, investors, partners and agents of each Holder and its Affiliates,
from and against any and all losses, claims, damages, liabilities and expenses (including, without
limitation, reasonable attorney fees and disbursements and other expenses incurred in connection
with investigating, preparing or defending any action, claim or proceeding, pending or threatened
and the costs of enforcement hereof) (collectively, “Losses”) to which any such Person may
become subject, arising out of or based upon any untrue statement of a material fact contained in
any Registration Statement covering any Registrable Securities, any related prospectus or
preliminary prospectus, or any amendment or supplement thereto, or any omission to state in any
thereof a material fact required to be stated therein or necessary to make the statements therein
(in the case of a prospectus or prospectus supplement, in light of the circumstances under which
they were made) not misleading, except in each case insofar, but only insofar, as the same arises
out of or is based upon an untrue statement or alleged untrue statement of a material fact or an
omission or alleged omission to state a material fact in such Registration Statement, prospectus,
preliminary prospectus, amendment or supplement, as the case may be, made or omitted, as the case
may be, in express reliance upon and in strict conformity with written information furnished to the
Company by the Holder expressly for use therein. This indemnity is in addition to any liability
that the Company may otherwise have. The Company shall also indemnify any underwriters of the
Registrable Securities, selling brokers, dealer managers and similar securities industry
professionals participating in the distribution and their

-11-

 

officers and directors and each Person who controls such underwriters or other Persons (within
the meaning of the Securities Act) to the same extent as provided above with respect to the
indemnification of the Holder and its Affiliates as described above.

               (b) In connection with any Registration Statement covering Registrable Securities, each Holder
shall furnish to the Company in writing such information with respect to the Holder as the Company
reasonably requests for use in connection with such Registration Statement, any related Prospectus
or preliminary prospectus, or any amendment or supplement thereto, and shall indemnify, to the
fullest extent permitted by law, the Company, the Company’s directors, officers, employees and
agents, each Person who controls the Company (within the meaning of the Securities Act), against
all Losses arising out of or based upon any untrue statement of a material fact contained in any
Registration Statement covering any Registrable Securities, any related Prospectus or preliminary
prospectus, or any amendment or supplement thereto, or any omission to state in any such
prospectus, amendment or supplement, a material fact required to be stated therein or necessary to
make the statements therein (in the case of a prospectus or prospectus supplement, in light of the
circumstances under which they were made) not misleading, in each case to the extent, and only to
the extent, that the same arises out of or is based upon an untrue statement of a material fact or
an omission to state a material fact in such Registration Statement or in such related Prospectus,
preliminary prospectus, amendment or supplement, as the case may be, made or omitted, as the case
may be, in express reliance upon and in strict conformity with written information furnished to the
Company by the Holder expressly for use therein. Notwithstanding any other provision of this
Agreement, in no event shall the Holder’s indemnification obligation exceed the dollar amount of
the proceeds received by the Holder upon the sale of the Registrable Securities giving rise to such
obligation.

               (c) Promptly after receipt by any Person (the “Indemnified Person”) of notice of any
demand, claim or circumstances which would or might give rise to a claim or the commencement of any
action, proceeding or investigation in respect of which indemnity may be sought pursuant to
Section 2.7, such Indemnified Person shall promptly notify the party obligated to provide
indemnification under this Section 2.7 in respect thereof (an “Indemnifying Party”)
and the Indemnifying Party shall assume the defense thereof, including the employment of counsel
reasonably satisfactory to such Indemnified Person, and shall assume the payment of all fees and
expenses in connection with such defense and such counsel; provided, however, that
the failure of any Indemnified Person to so notify the Indemnifying Party shall not relieve the
Indemnifying Party of its obligations hereunder except to the extent that the Indemnifying Party is
actually and materially prejudiced by such failure to notify. In any such proceeding, any
Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of
such counsel shall be at the expense of such Indemnified Person unless: (i) the Indemnifying Party
and the Indemnified Person shall have mutually agreed to the retention of such counsel; or (ii) in
the reasonable judgment of counsel to such Indemnified Person (x) representation of both parties by
the same counsel would be inappropriate due to actual or potential differing interests between them
or (y) if there are one or more defenses available to such Indemnified Person that is/are not
available to the Indemnifying Party. The Indemnifying Party shall not be liable for any settlement
of any proceeding effected without its written consent, which consent shall not be unreasonably
withheld, delayed or conditioned, but if settled with such consent, or if there be a final judgment
for the plaintiff therein, the Indemnifying Party shall indemnify and hold harmless such
Indemnified Person from and against any Losses by reason of such settlement or

-12-

 

judgment. Without the prior written consent of the Indemnified Person, which consent shall
not be unreasonably withheld, delayed or conditioned, the Indemnifying Party shall not effect any
settlement of any pending or threatened proceeding in respect of which any Indemnified Person is a
party, unless such settlement includes an unconditional release of such Indemnified Person from all
liability arising out of such proceeding.

               (d) (i) If the indemnification provided for in this Section 2.7 from the Indemnifying
Party is unavailable to an Indemnified Person hereunder or is inadequate in respect of any Losses
for which indemnification is provided under this Section 2.7, then the Indemnifying Party,
in lieu of indemnifying such Indemnified Person, shall contribute to the amount paid or payable by
such Indemnified Person as a result of such Losses in such proportion as is appropriate to reflect
the relative fault of the Indemnifying Party and Indemnified Person(s) in connection with the
actions that resulted in such Losses, as well as any other relevant equitable considerations. The
relative fault of such Indemnifying Party and Indemnified Person shall be determined by reference
to, among other things, whether any action in question, including any untrue or alleged untrue
statement of a material fact or omission or alleged omission to state a material fact, has been
made by, or relates to information supplied by, such Indemnifying Party or Indemnified Persons, and
the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such action. The amount paid or payable by a party as a result of the Losses referred to
above shall be deemed to include, subject to the limitations set forth in Section 2.7(c),
any legal or other fees or expenses reasonably incurred by such party in connection with any
investigation or proceeding.

             
  (ii) The parties hereto agree that it would not be just and equitable if contribution pursuant
to this Section 2.7(d) were determined by pro rata allocation or by any other method of
allocation that does not take account of the equitable considerations referred to in the
immediately preceding paragraph. Notwithstanding any other provision hereof, in no event shall the
Holder’s contribution obligation exceed the excess of (A) the dollar amount of the proceeds
received by the Holder upon the sale of the Registrable Securities giving rise to such contribution
obligation over (B) the dollar amount of any damages that the Holder has otherwise been required to
pay by reason of the untrue or alleged untrue statement or omission or alleged omission giving rise
to such obligation. No Person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation.

              
(iii) If any provision of an indemnification or contribution clause in an underwriting
agreement or agency agreement executed by or on behalf of the Holder differs from a provision in
this Section 2.7, such provision in the underwriting agreement shall determine the Holder’s
rights in respect thereof.

       
        (e) Notwithstanding anything in this Agreement to the contrary, the indemnities and
obligations provided in this Section 2.7 shall survive the transfer of any Registrable
Securities by the Holder.

          2.8 Reporting. With a view to making available the benefits of certain rules and
regulations of the Commission which may at any time permit the sale of the Registrable Securities
to the public without registration, so long as the Company is subject to the reporting

-13-

 

requirements of the Exchange Act, the Company shall:

               (a) make and keep public information available, as contemplated in Rule 144 under the
Securities Act (or any successor rule); and

               (b) use its best efforts to file with the Commission in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act.

          2.9 Furnishing Information. It shall be a condition precedent to the obligations of
the Company to take any action pursuant to this Article II that each Holder furnish to the
Company in writing such information regarding such Holder, the Registrable Securities held by it
and the intended method of disposition of such securities as shall be required to effect the
registration thereof.

          2.10 Additional Registration Rights. The Company shall not, after the date hereof,
enter into any agreement providing any registration rights to any of its security holders or
potential security holders, without the prior written consent of holders of a majority of the
Registrable Securities (which consent must include the Lead Investor so long as the Lead Investor
holds at least 50% of the Series H Preferred Shares acquired by it pursuant to the Purchase
Agreement, unless such registration rights are subordinate to the registration rights of the
Holders hereunder).

          2.11 Restrictions on Transfer.

               (a) Each Holder agrees not to make any disposition of all or any portion of the Preferred
Stock unless and until:

               (i) there is then in effect a registration statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with the “Plan of Distribution”
contained in such registration statement;

               (ii) (A) the transferee has agreed in writing to be bound by the terms of this Agreement, (B)
such Holder shall have notified the Company of the proposed disposition and shall have furnished
the Company with a detailed statement of the circumstances surrounding the proposed disposition,
and (C) if reasonably requested by the Company, such Holder shall have furnished the Company with
an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not
require registration of such shares under the Securities Act; or

               (iii) The shares of Preferred Stock are then eligible for transfer pursuant to Rule 144(k)
promulgated under the Securities Act. Furthermore, it is agreed that the Company will not require
opinions of counsel for transactions made pursuant to Rule 144 of the Securities Act.

               (b) Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to
a transfer by a Holder that is (A) a partnership transferring to its partners or former partners in
accordance with partnership interests, (B) a corporation

-14-

 

transferring to a parent corporation that owns a majority of the capital stock of the Holder,
to a majority-owned subsidiary, or to an affiliate under common control with the Holder, (C) a
limited liability company transferring to its members or former members in accordance with their
interest in the limited liability company, (D) a Holder transferring to its affiliated venture
capital fund or affiliated trust, (E) an individual transferring to the Holder’s family member or
trust for the benefit of an individual Holder, (F) a trust transferring to a trust beneficiary or
affiliated trust, or (G) a Holder transferring to any transferee that is a Major Investor, provided
that the Company is given written notice thereof; provided that in each case the transferee will
agree in writing to be subject to the terms of this Agreement to the same extent as if he were an
original Holder hereunder.

               (c) So long as the Registrable Securities are not (i) covered by an effective registration
statement; and/or (ii) eligible for transfer pursuant to Rule 144(k) promulgated under the
Securities Act, each certificate representing Registrable Securities shall be stamped or otherwise
imprinted with legends substantially similar to the following (in addition to any legend required
under applicable state securities laws):

THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND
CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE
STOCKHOLDERS AND THE COMPANY. ANY INDIVIDUAL AND/OR ENTITY
ACCEPTING ANY INTEREST IN SUCH SECURITIES SHALL BE DEEMED TO AGREE
TO AND SHALL BECOME BOUND BY ALL RESTRICTIONS AND OBLIGATIONS UNDER
SUCH AGREEMENT. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON
WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY.

          2.12 Lock-Up Agreement.

               (a) Lock-Up Period; Agreement.

               (i) In connection with the Initial Public Offering of the Company’s securities and upon
request of the Company or the underwriters managing such offering of the Company’s securities, each
Holder agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or
otherwise dispose of any securities of the Company, however or whenever acquired (other than those
included in the registration) without the prior written consent of the Company or such
underwriters, as the case may be, for such period of time (not to exceed 180 days but subject to
such extension or extensions as may be required by the underwriters in order to publish research
reports while complying with the Rule 2711 of the National Association of Securities Dealers, Inc.)
from the effective date of such registration statement as may be requested by the Company or such
managing underwriters and to execute an agreement reflecting the foregoing as may be requested by
the underwriters at the time of the Company’s Initial Public Offering.

-15-

 

               (ii) In connection with the Initial Public Offering of the Company’s securities and upon
request of the Company or the underwriters managing such offering of the Company’s securities, each
holder of Series H Preferred Stock (or Common Stock issued upon conversion thereof) agrees to
execute a lockup agreement as may be reasonably requested by any such underwriters.

               (b) Limitations. The obligations described in Section 2.12(a) shall not apply
to shares of the Company’s Common Stock acquired in the Company’s Initial Public Offering or to
shares of the Company’s Common Stock acquired in the public market following such Initial Public
Offering. In addition, the obligations described in Section 2.12(a) shall apply only if
all officers and directors of the Company and all greater than 1% stockholders enter into similar
agreements.

               (c) Stop-Transfer Instructions. In order to enforce the foregoing covenants the
Company may impose stop-transfer instructions with respect to the securities of each Holder (and
the securities of every other person subject to the restrictions in Section 2.12(a).

               (d) Transferees Bound. Each Holder agrees that prior to the Company’s Initial Public
Offering it will not transfer securities of the Company unless each transferee agrees in writing to
be bound by all relevant provisions of this Section 2.12.

               (e) Each Holder agrees that a legend reading substantially as follows shall be placed on all
certificates representing all Registrable Securities of each Holder (and the shares or securities
of every other person subject to the relevant restrictions contained in this Section 2.12):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A
LOCK-UP PERIOD OF UP TO 180 DAYS AFTER THE EFFECTIVE DATE OF
THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS
AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND
THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE
OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD
IS BINDING ON TRANSFEREES OF THESE SHARES.

               (f) Each Holder of Series H Preferred Stock agrees that a legend reading substantially as
follows shall be placed on all certificates representing all shares of Series H Preferred Stock (or
Common Stock issued upon conversion thereof) of each such Holder (and the shares or securities of
every other person subject to the relevant restrictions contained in this Section 2.12):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE SUBJECT
TO A LOCK-UP

-16-

 

PERIOD AFTER THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION
STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN
AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE
SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S
PRINCIPAL OFFICE. SUCH LOCK-UP PERIOD, IF APPLICABLE, IS
BINDING ON TRANSFEREES OF THESE SHARES.

Article III Miscellaneous.

          3.1 Effectiveness of Amendment. This Agreement shall become effective immediately
prior to, but contingent upon, the consummation a Qualified Initial Public Offering.

          3.2 Termination. This Agreement shall terminate, and have no further force and
effect, upon the closing of a Sale of the Company (as defined below). For purposes of this
Section 3.2, a “ Sale of the Company” shall include a sale, lease, or other
disposition of all or substantially all of the Company’s assets or business or the Company’s merger
into or consolidation with any other corporation or other entity, or any other corporate
reorganization, in which the holders of the Company’s outstanding voting stock immediately prior to
such transaction own, immediately after such transaction, securities representing less than fifty
percent (50%) of the voting power of the corporation or other entity surviving such transaction,
provided that a Sale of the Company shall not include a merger effected exclusively for the purpose
of changing the domicile of the Company or a sale of shares by the Company for primarily equity
financing purposes.

          3.3 Successors and Assigns. This Agreement may not be assigned by a party hereto
without the prior written consent of the Company or the Requisite Investors; provided,
however, that an Investor may assign its rights and delegate its duties hereunder in whole
or in part, without the prior written consent of the Company, to an Affiliate and to any Person to
whom such investor transfers any of the Registrable Securities; provided, that, no such
assignment shall be effective or confer any right on any such assignee unless, prior to such
assignment, the assignee agrees in writing that such assignee will be bound by all provisions
binding on such Investor. The provisions of this Agreement shall inure to the benefit of and be
binding upon the respective permitted successors and assigns of the parties. Except for any other
provisions of this Agreement expressly to the contrary, nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this
Agreement.

          3.4 Counterparts; Faxes. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. This Agreement may also be executed via facsimile, which shall be deemed an
original.

-17-

 

          3.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement.

          3.6 Notices. Unless otherwise provided, any notice required or permitted under this
Agreement shall be given in writing and shall be deemed effectively given as hereinafter described:
(i) if given by personal delivery, then such notice shall be deemed given upon such delivery; (ii)
if given by telecopier, then such notice shall be deemed given upon receipt of confirmation of
complete transmittal; (iii) if given by mail, then such notice shall be deemed given upon the
earlier of (A) receipt of such notice by the recipient or (B) three (3) days after such notice is
deposited in first class mail, postage prepaid; and (iv) if given by an internationally recognized
overnight air courier, then such notice shall be deemed given one (1) day after delivery to such
carrier. All notices shall be addressed to the party to be notified at the address as follows, or
at such other address as such party may designate by ten (10) days’ advance written notice to the
other party:

If to the Company:

REVA Medical, Inc.

5751 Copley Drive, Suite B

San Diego, CA 92111

Attn: President

Fax: (858) 430-0729

With a copy to:

DLA Piper LLP (US)

4365 Executive Drive, Suite 1100

San Diego, CA 92121

Attn: Michael Kagnoff, Esq.

Fax: (858) 677-1401

          If to any of the Investors, at the address set forth on its signature page hereto.

          3.7 Expenses. In the event that legal proceedings are commenced by any party to this
Agreement against another party to this Agreement in connection with this Agreement, the party or
parties which do not prevail in such proceedings shall severally, but not jointly, pay their pro
rata share of the reasonable attorneys’ fees and other reasonable out-of-pocket costs and expenses
incurred by the prevailing party in such proceedings.

          3.8 Amendments and Waivers. Neither this Agreement nor any provision hereof may be
waived, modified, terminated or amended except by a written agreement signed by (a) the Company,
(b) the Requisite Investors, and (c) if the rights of the Holders are being amended or waived or
additional obligations are being imposed on the Holders, Holders holding at least a majority of the
issued and outstanding Common Stock (on an as-converted basis) then held by all Holders;
provided, that no Investor shall be materially adversely affected without its consent by
any waiver, modification, termination or amendment in which the other members of the same class are
not likewise adversely affected. The Company may take any action herein prohibited, or omit to
perform any act herein required to be performed by it, only if the Company

-18-

 

shall have obtained the written consent to such amendment, action or omission to act, of the Requisite
Investors.

          3.9 Severability. Any provision of this Agreement that is prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such
prohibition or unenforceability without invalidating the remaining provisions hereof but shall be
interpreted as if it were written so as to be enforceable to the maximum extent permitted by
applicable law, and any such prohibition or unenforceability in any jurisdiction shall not
invalidate or render unenforceable such provision in any other jurisdiction. To the extent
permitted by applicable law, the parties hereby waive any provision of law which renders any
provision hereof prohibited or unenforceable in any respect.

          3.10 Entire Agreement. This Agreement constitutes the entire agreement among the
parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and
understandings, both oral and written, between the parties with respect to the subject matter
hereof, including but not limited to the Prior Agreement. Prior drafts or versions of this
Agreement shall not be used to interpret this Agreement.

          3.11 Further Assurances. The parties shall execute and deliver all such further
instruments and documents and take all such other actions as may reasonably be required to carry
out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein
contained.

          3.12 Governing Law; Consent to Jurisdiction. This Agreement shall be governed by, and
construed in accordance with, the internal laws of the State of New York without regard to the
choice of law principles thereof. Each of the parties hereto irrevocably submits to the
jurisdiction of the courts of the State of New York located in New York County and the United
States District Court for the Southern District of New York for the purpose of any suit, action,
proceeding or judgment relating to or arising out of this Agreement and the transactions
contemplated hereby. Service of process in connection with any such suit, action or proceeding may
be served on each party hereto anywhere in the world by the same methods as are specified for the
giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the
jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in
such court. Each party hereto irrevocably waives any objection to the laying of venue of any such
suit, action or proceeding brought in such courts and irrevocably waives any claim that any such
suit, action or proceeding brought in any such court has been brought in an inconvenient forum.
THE COMPANY AND EACH OF THE INVESTORS HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY
IN ANY LEGAL PROCEEDING RELATING TO OR ARISING OUT OF THIS AGREEMENT OR ANY OTHER TRANSACTION
DOCUMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY.

          3.13 Independent Nature of Investors’ Obligations and Rights. Except as expressly
provided herein and therein, the obligations of each REVA Investor under this Agreement and each
other Transaction Document to which it is a party, are several and not joint with the obligations
of any other REVA Investor, and no REVA Investor shall be responsible in any way for the
performance of the obligations of any other REVA Investor under this

-19-

 

Agreement or any other Transaction Document to which it is a party. The decision of each
Investor to purchase Series H Preferred Shares and Warrants pursuant to the Purchase Agreement and
the other Transaction Documents has been made by such Investor independently of any other Investor.
Nothing contained herein or in any other Transaction Document, and no action taken by any Investor
(including, without limitation, the Lead Investor) pursuant hereto or thereto, shall be deemed to
constitute the Investors as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Investors are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by this Agreement or the other
Transaction Documents. Each Investor acknowledges that no other Investor (including, without
limitation, the Lead Investors) has acted as agent for such Investor in connection with making its
investment under the Purchase Agreement and that no Investor (including, without limitation, the
Lead Investors) will be acting as agent of such Investor in connection with monitoring its
investment in the Series H Preferred Shares or enforcing its rights under this Agreement or the
other Transaction Documents. Each REVA Investor shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of this Agreement or out
of the other Transaction Documents to which it is a party, and it shall not be necessary for any
other REVA Investor to be joined as an additional party in any proceeding for such purpose. The
Company acknowledges that each of the Investors has been provided with the same Transaction
Documents for the purpose of closing a transaction with multiple Investors and not because it was
required or requested to do so by any Investor. Notwithstanding anything contained in this
Agreement or any other Transaction Document to the contrary, the Lead Investors shall not have any
duty, fiduciary or otherwise, to any other REVA Investor by virtue of such investor serving as the
Lead Investor or otherwise.

[SIGNATURE PAGE FOLLOWS]

-20-

 

[Company Signature Page]

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement or caused this Agreement
to be executed by their duly authorized representatives, as of the date first written above.

	 	 	 	 	 
	 	THE COMPANY:

REVA MEDICAL, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	       	 	  	 	 
	 	 	Address:	     5751 Copley Drive, Suite B

  San Diego, CA  92111 	 
	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	MEDTRONIC, INC.

 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	       	 	Title:  	 	 
	       	 	  	 	 
	 	 	Address:	
 	 
	 	 	 	
 	 
	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	CERBERUS INTERNATIONAL, LTD.

 	 
	 	By:  	 Partridge Hill Overseas Management, LLC,
 	 
	 	 	its investment manager 	 

	 	 	 	 	 
	 	By:  	
 	 
	 	 	Name:  	Jeffrey L. Lomasky, Senior Managing Director 	 

	 	 	 	 	 
	 	CERBERUS PARTNERS, L.P.

 	 
	 	By:  	 Cerberus Associates, L.L.C.,
 	 
	 	 	its general partner 	 

	 	 	 	 	 
	 	By:  	
 	 
	 	 	Name:  	Jeffrey L. Lomasky, Senior Managing Director 	 

	 	 	 	 	 
	 	CERBERUS SERIES FOUR HOLDINGS, LLC

 	 
	 	By:  	 Cerberus Institutional Partners, L.P.,
 	 
	 	 	with respect to Series Four, its managing member 	 
	 	 	 
	 	By:  	 Cerberus Institutional Associates, L.L.C.,
 	 
	 	 	its general partner 	 
	 
	 	By:  	
 	 
	 	 	Name:  	Jeffrey L. Lomasky, Senior Managing Director 	 

	 	 	 	 	 
	 	GABRIEL ASSETS, LLC

 	 
	 	By:  	 Partridge Hill Management, LLC,
 	 
	 	 	its investment manager 	 
	 
	 	By:  	
 	 
	 	 	Name:  	Jeffrey L. Lomasky, Senior Managing Director 	 

	 	 	 	 	 
	 	CERBERUS AMERICA SERIES TWO HOLDINGS, LLC

 	 
	 	By:  	 Cerberus Institutional Partners (America), L.P.,
 	 
	 	 	with respect to Series Two, its managing member 	 
	 	 	 	 
	 	By:  	 Cerberus Institutional Associates, L.L.C.,
 	 
	 	 	its general partner 	 

	 	 	 	 	 
	 	By:  	
 	 
	 	 	Name:  	Jeffrey L. Lomasky, Senior Managing Director 	 
	 	 	 	 
	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	BROOKSIDE CAPITAL PARTNERS FUND, LP

	 
	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	       	 	  	 	 
	 	 	Address:	 	 
	 	 	 	 	 
	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	DANIEL R. FRANK

 	 
	 	
 	 
	 	Daniel R. Frank 	 

	 	 	 	 	 
	 	  Address:  	
 	 
	 	
  	
 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	JAMES T. LENEHAN

 	 
	 	
 	 
	 	James T. Lenehan 	 
	 
	 	  Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 	 
	 	BEAVER CREEK FUND, LTD.

 	 
	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	Address:  	 	 
	 	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

================================================================================

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	DOMAIN PARTNERS V, L.P.

 	 
	 	By:  	One Palmer Square Associates V, L.L.C.
 	 
	 	Its: 	  General Partner 	 
	 	 	 	 
	 	 	 
	 	By:  	
 	 
	 	 	Kathleen K. Schoemaker 	 
	 	 	Managing Member 	 
	 
	 	DP V ASSOCIATES, L.P.

 	 
	 	By:  	One Palmer Square Associates V, L.L.C.
 	 
	 	Its: 	  General Partner 	 
	 	 	 	 
	 	 	 
	 	By:  	
 	 
	 	 	Kathleen K. Schoemaker 	 
	 	 	Managing Member 	 
	 	 	 	
 	 
	 	 	Address:	
 	 
	 	 	 	
 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	KENNETH RAININ ADMINISTRATIVE TRUST

 U/D/T DATED
3/26/1990
 
	 	 	 
	 	
 	 
	 	Jennifer Rainin, Trustee 	 
	 	 	 
	 	
 	 
	 	Robert B. Stockman, Trustee 	 

	 	 	 	 	 
	 	Address:  	 	 
	 	 	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	GROUP OUTCOME INVESTORS I, LLC 	 
	 
	 	
 	 
	 	Robert B. Stockman

President and Chief Executive Officer 	 

	 	 	 	 	 
	 	Address:  	 
 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	ROBERT B. STOCKMAN

 	 
	 	
 	 
	 	Robert B. Stockman 	 

	 	 	 	 	 
	 	Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	FREDERIC H. MOLL, M.D.

 	 
	 	
 	 
	 	Frederic H. Moll, M.D. 	 

	 	 	 	 	 
	 	Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	C. RAYMOND LARKIN, JR.

 	 
	 	
 	 
	 	C. Raymond Larkin, Jr. 	 

	 	 	 	 	 
	 	Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	GORDON E. NYE

 	 
	 	
 	 
	 	Gordon E. Nye 	 

	 	 	 	 	 
	 	Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	TIMOTHY J. BARBERICH

 	 
	 	
 	 
	 	Timothy J. Barberich 	 
	 
	 	  Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	EDWARD P. WEINSOFF

 	 
	 	
 	 
	 	Edward P. Weinsoff 	 
	 
	 	Address:  	 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	ROBERT WONG

 	 
	 	
 	 
	 	Robert Wong 	 
	 	 	 	
 	 
	 	 	Address:	
 	 
	 	 	 	
 	 

[Investors’ Rights Agreement Signature Page]

 

 

[Investor Signature Page]

     IN WITNESS WHEREOF, the undersigned has executed this Agreement as of the date first above
written.

	 	 	 	 	 
	 	SAINTS CAPITAL EVEREST, L.P.

 	 
	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

	 	 	 	 	 
	 	Address:  	
 	 
	 	 	 	 

[Investors’ Rights Agreement Signature Page]exv10w10

EXHIBIT 10.10

Execution Version

DISTRIBUTION OPTION AGREEMENT

     THIS DISTRIBUTION OPTION AGREEMENT (the “Agreement”), is made and entered into on
December 7, 2007 (the “Effective Date”), by and between (i) Boston Scientific Corporation,
a Delaware corporation (“BSC”), and (ii) Reva Medical, Inc., a California corporation
(“Reva”).

     WHEREAS, each of Reva and BSC desires to enter into this Agreement to facilitate the
contemplated sale by Reva for cash of shares of its Series H Preferred Stock, no par value per
share;

     WHEREAS, pursuant to the terms of that certain Agreement and Plan of Merger (the
“Merger Agreement”), dated as of October 13, 2004, by and among (i) BSC, (ii) RMI
Acquisition Corp. (the “Merger Sub”), a California corporation and a wholly-owned
subsidiary of Boston Scientific Scimed, Inc., a Minnesota corporation and a subsidiary of BSC
formerly known as Scimed Life Systems, Inc. (“Scimed”), (iii) Reva, and (iv) the members of
the Stockholder Representative Committee referred to therein, BSC has an exclusive option (the
“Company Option”) to acquire all of the outstanding capital stock, options, warrants and
other rights exercisable for, or instruments convertible into, shares of capital stock of Reva;

     WHEREAS, if BSC exercises the Company Option, Reva, BSC and Merger Sub will consummate the
Merger described in the Merger Agreement, pursuant to which Merger Sub will merge (the
“Merger”) with and into Reva and Reva, as the surviving corporation in the Merger, will
become a wholly-owned subsidiary of Scimed;

     WHEREAS, immediately following the execution and delivery of this agreement, BSC, Reva, Merger
Sub and the Stockholder Representative Committee intend to enter into an amendment to the Merger
Agreement (the “Amendment”) providing that, among other things, (i) upon the consummation
of an initial closing of a Qualified Equity Financing in which the Company receives aggregate net
cash proceeds (not subject to any contingencies) of no less than $10,000,000, the Company Option
shall be suspended until September 30, 2008, unless the Company has received aggregate net cash
proceeds (not subject to any contingencies) equal to no less than $25,000,000 in a Qualified Equity
Financing prior to such date (including such amounts received at such initial closing), in which
event the Company Option shall be suspended until the third anniversary of the
consummation of the initial closing of the Qualified Equity Financing (the date upon with the
Company Option shall no longer be suspended being referred to herein as the “Restoration
Date”), and (ii) upon the consummation by Reva at any time prior to the Restoration Date of
an initial public offering of shares of its capital stock resulting in the receipt by Reva of no
less than $50,000,000 in aggregate gross cash proceeds, the Company Option shall be terminated; and

     WHEREAS, BSC is unwilling to enter into the Amendment unless this Agreement is executed and
delivered by the parties hereto.

     NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements contained
herein, the parties hereby agree as follows:

 

 

1. Definitions. As used herein the following terms not otherwise defined have the
following respective meanings:

     “Affiliate” shall mean, with respect to any person or entity, any person or entity
that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such person or entity.

     “business days” (whether such term is capitalized or not) shall mean any day
other than Saturday, Sunday or a legal holiday that banks located in Boston, Massachusetts are open
for business.

     “Clinical Milestone” shall mean the date occurring ninety (90) days following
the delivery by Reva to BSC of each of (i) all material information (including, but not limited to,
all case report forms and all data concerning imaging, death, MI, ST and TLR) available to Reva
relating to the one year follow-up of at least 200 implanted resorbable drug coated stents of Reva
from a human clinical trial conducted in accordance with applicable laws and regulations (the
“Implanted Stents”), (ii) all material information (including, but not limited to,
core lab acute gain, late loss, and binary angiographic restenosis) relating to the 8-9 month
angiographic follow-up of at least 100 of such Implanted Stents, and (iii) all material information
relating to the 8-9 month IVUS of at least 40 of such Implanted Stents.

     “Coronary Stent Product” shall mean Reva’s bioresorbable coronary
stent products and (i) any stent products subsequently developed by Reva that serve as line
extensions thereto, (ii) any associated products of Reva that are integral to the performance of
Reva’s bioresorbable coronary stent products or sold therewith as part of a kit, and (iii) any
Improvements or substitutes therefor.

     “Corresponding Stent Product” shall mean, (i) with respect to any
Directly Competitive Resorbable Stent Product that is a coronary stent product, the Coronary Stent
Product, and (ii) with respect to any Directly Competitive Resorbable Stent Product that is a
peripheral vascular stent product, the Peripheral Vascular Stent Product.

     “Direct Competitor” shall mean Medtronic, Johnson & Johnson Corporation and
Abbott Laboratories and each of their respective Affiliates.

     “Directly Competitive Resorbable Stent Product” shall
mean any bioresorbable coronary or peripheral vascular stent product, other than, (i) with respect
to a coronary stent product, the Coronary Stent Product, and, (ii) with respect to a peripheral
vascular stent product, the Peripheral Vascular Stent Product, in each case with approved
indications substantially similar to those of the Coronary Stent Product or Peripheral Vascular
Stent Product, as applicable.

     “Effectiveness Time” shall be the moment in time immediately following the initial
closing of a Qualified Equity Financing, provided, that such closing results in the Company
actually receiving aggregate net cash proceeds (not subject to any contingencies) equal to no less
than $10,000,000.

     “FDA” means the United States Food and Drug Administration, or any successor entity.

2

 

     “Improvement” shall mean an addition, development, enhancement, update or other change
in any Product, including any extension of the label claims for any Product and any new design for
any Product.

     “IVUS” shall mean intravascular ultrasound.

     “MI” shall mean acute myocardial infarction.

     “Jurisdiction” shall mean each country or other jurisdiction in the world;
provided, that the member states of the European Union shall each be considered a single
Jurisdiction for purposes hereof.

     “Option Period” shall mean the period of time beginning as of the Effectiveness Time
and ending, unless otherwise terminated earlier pursuant to Section 3 hereof, on the date on which
the Clinical Milestone is achieved.

     “Peripheral Vascular Stent Product” shall mean Reva’s bioresorbable
peripheral vascular stent products and (i) any stent products subsequently developed by Reva that
serve as line extensions thereto, (ii) any associated products of Reva that are integral to the
performance of Reva’s bioresorbable peripheral vascular stent products or sold therewith as part of
a kit and (iii) any Improvements or substitutes therefor.

     “person” (whether such term is capitalized or not) shall mean an individual,
corporation, partnership, limited partnership, limited liability company, syndicate, person
(including, without limitation, a “person” as defined in Section 13(d)(3) of the Exchange Act),
trust, association or entity or government, political subdivision, agency or instrumentality of a
government.

     “Product” shall mean any of the Coronary Stent Product or Peripheral Vascular Stent
Product.

     “Product Approvals” shall mean, with respect to a Jurisdiction, all regulatory
approvals required for importation, exportation, promotion, pricing, marketing and sale of any
Product in such Jurisdiction.

     “Qualified Equity Financing” shall mean the sale for cash of a new
series of Company Preferred Stock (as defined in the Merger Agreement) on or after the Effective
Date to a syndicate of investors led by a non-affiliated third party in a transaction which may
include one or more closings pursuant to which Reva shall actually receive aggregate net proceeds
(not subject to any contingencies) equal to no less than $25,000,000; provided,
however, that the initial closing (or first closing) of a Qualified Equity Financing shall
be deemed to have occurred at such time as the Company shall have received in an initial closing
(whether or not any subsequent closings actually take place) not less than $10,000,000 pursuant to
the terms and conditions set forth above.

     “ST” shall mean stent thrombosis.

     “TLR” shall mean target lesion revascularization.

3

 

     The following table sets forth certain other defined terms and the section of this Agreement
in which the meaning of each such term appears:

	 	 	 	 	 
	Defined Term	 	Section
	“Agreement”

	 	Preamble

	“Amendment”

	 	Preamble

	“BSC”

	 	Preamble

	“Company Option”

	 	Preamble

	“Effective Date”

	 	Preamble

	“Foreign Jurisdiction”

	 	1.2
	“Implanted Stents”

	 	1, “Clinical Milestone”

	“Merger”

	 	Preamble

	“Merger Agreement”

	 	Preamble

	“Merger Sub”

	 	Preamble

	“Negotiation Period”

	 	1.3(b)
	“Option”

	 	1.1
	“Option Exercise Notice”

	 	1.1
	“Qualified Equity Financing”

	 	Preamble

	“Restoration Date”

	 	Preamble

	“Reva”

	 	Preamble

	“Scimed”

	 	Preamble

     2. Option to Distribute Products.

     2.1 Distribution Options. Reva hereby grants to BSC an exclusive right with respect
to each Jurisdiction on an exclusive basis (in each case, an “Option”), exercisable in each
case in BSC’s sole discretion at any time during the Option Period, to sell, market and distribute
Products in such Jurisdiction. BSC may exercise the Option with respect to any Jurisdiction by
delivering written notice (each an “Option Exercise Notice”) to Reva at any
time during the Option Period. Notwithstanding the foregoing, from and after such time, if any,
that BSC first sells, markets or distributes any Directly Competitive Resorbable Stent Product in
any Jurisdiction, then each Option shall become an option to obtain nonexclusive rights in such
Jurisdiction solely with respect to the applicable Corresponding Stent Product and all exclusive
arrangements in such Jurisdiction shall become nonexclusive in such Jurisdiction solely with
respect to such Corresponding Stent Product.

     2.2 Exclusive Distribution Right. Reva hereby agrees that at all times prior to the
expiration or termination of the Option Period, it will not market, sell or distribute any Product
in any Jurisdiction or enter into any agreement or take any other action (including but not limited
to, (i) granting any third party the right, or otherwise permitting any third party, to sell,
market or distribute any Product in any Jurisdiction, (ii) entering into any distribution agreement
with any third party in respect of any Product, and (iii) transferring or licensing to any third
party any proprietary rights or other intellectual property) that would prevent or hinder BSC from
exercising any Option; provided, however, that notwithstanding anything to the
contrary in this Section 2, if BSC sells, markets or distributes any Directly Competitive
Resorbable Stent

4

 

Product in any Jurisdiction, then Reva shall be entitled to market, sell and
distribute the applicable Corresponding Stent Product in such Jurisdiction, or grant other parties
the right to do so, in each case on a non-exclusive basis. Notwithstanding anything to the
contrary herein, if (x) Reva receives Product Approval in respect of any Jurisdiction, or any
country or territory within a Jurisdiction (in the case of the European Union), outside of the
United States (each a “Foreign Jurisdiction”) with respect to any Product prior to
the submission by Reva to the FDA of an application for Product Approval in the United States with
respect to such Product, and (y) BSC does not deliver to Reva an Option Exercise Notice with
respect to such Product and such Foreign Jurisdiction prior to the ninetieth (90th) day following
receipt by BSC of a written inquiry from Reva (which written inquiry may not be delivered to BSC
until after such time as Reva has obtained Product Approval in respect of such Product and such
Foreign Jurisdiction) inquiring whether BSC intends to exercise the Option with respect to such
Product and such Foreign Jurisdiction or BSC delivers an Option Exercise Notice with respect to
such Product and such Foreign Jurisdiction but BSC and Reva are unable to agree upon the terms of a
definitive distribution agreement prior to the expiration of the Negotiation Period, then Reva may
sell, market and distribute such Product in such Foreign Jurisdiction directly or through any third
party that is not a Direct Competitor, provided, however, that any and all
distribution, reseller or similar agreement(s) entered into between Reva and any such third party
shall be terminable, without cost or penalty to BSC, on no more than ninety (90) days’ written
notice.

     2.3 Negotiation of Agreement.

          (a) If BSC exercises any Option(s), negotiations will begin as soon as reasonably practicable
thereafter and the parties shall negotiate in good faith to enter into a mutually acceptable
definitive distribution agreement with respect to such Option(s), which shall be prepared by BSC in
a form reasonably acceptable to Reva, with customary terms and provisions, including without
limitation, customary provisions relating to indemnification and representations and warranties
covering, among other things, ownership, manufacturing, regulatory approvals, product quality, no
liabilities, infringement and Intellectual Property coverage. In addition to such customary
provisions, such definitive distribution agreement shall also include provisions that (i) Reva
shall be obligated to meet all legal and regulatory requirements, as well as BSC quality standards,
with respect to the design, development, and manufacturing of all Products and will contain all
quality control provisions from BSC’s then current standard supplier quality agreement, (ii) the
transfer price for Products shall be equal to fifty percent (50%) of BSC’s average selling price
for such Products, (iii) the term of such distribution agreement shall not be less than five (5)
years, (iv) BSC shall not be required to make any payments, other than payments of the
aforementioned transfer price for Products, with respect to the sale, marketing or distribution of
Products, (v) BSC shall be the exclusive distributor of the Products at all times during the term
of such distribution agreement so long as BSC does not commence the selling, marketing or
distributing of any Directly Competitive Resorbable Stent Product, with any such distribution
agreement becoming non-exclusive with respect to (x) any Jurisdiction and (y) the applicable
Corresponding Stent Product, at such time as BSC first sells, markets or distributes any Directly
Competitive Resorbable Stent Product in such Jurisdiction, and (vi) BSC shall have sole discretion
over all marketing and sales decisions relating to the Products.

5

 

          (b) If BSC and Reva are unable to agree upon the terms of a definitive distribution agreement
through good faith negotiations with respect to any Option within ninety (90) days of BSC’s
exercise of such Option (the “Negotiation Period”), or if BSC delivers at any time
written notice to Reva that it elects not to exercise any Option, then Reva shall be permitted to
sell, market and distribute Products in the Jurisdiction pertaining to any such Option itself or
offer the right to sell, market and distribute Products in the Jurisdiction pertaining to any such
Option to a third party, provided that, in the case of any such offer made to any such
third party, the terms of such offer, and of any definitive agreement establishing such third
party’s right to sell, market and distribute Products, shall not be materially more favorable than
the most favorable terms offered by Reva to BSC at any time after the date of this Agreement and
prior to the end of the Negotiation Period regarding BSC’s right to sell, market and distribute
Products in the Jurisdiction pertaining to any such Option.

     2.4 Due Diligence. During any negotiation period for a distribution agreement
contemplated by this Section 2, subject to the parties entering into a confidentiality agreement in
form and substance reasonably acceptable to Reva, BSC shall be provided the opportunity to perform
reasonable financial, legal, business and other due diligence regarding the Products. BSC shall
not be required to enter into any distribution agreement with respect to any Option under any
circumstances where it is not satisfied, in its sole discretion, with the results of such due
diligence review. Reva shall provide BSC with reasonable cooperation in such due diligence review,
including, allowing BSC access to its books, records, facilities and personnel.

3. Term and Termination.

     3.1 Term. This Agreement shall commence on the Effective Date and shall continue in
full force and effect until the termination or expiration of the Option Period; provided,
however, that (i) this Agreement may be terminated earlier in accordance with the
provisions of this Section 3 and (ii) this Agreement shall continue in full force and effect at all
times during any Negotiation Period.

     3.2 Termination by BSC. BSC may terminate this Agreement, for any reason or no
reason, at any time from and after the Effective Date by written notice to Reva.

     3.3 Survival of Certain Terms. The provisions of Sections 2.3(b), 3 and 4 of this
Agreement shall survive the termination of this Agreement for any reason. All other rights and
obligations of the parties, other than those rights that shall have then accrued, shall cease upon
termination of this Agreement.

     3.4 Effect of Termination. The parties acknowledge that upon termination of this
Agreement as permitted under, and in accordance with the terms of this Section 3, no party shall
have the right to recover any claim with respect to any losses suffered by such party in connection
with such termination, except to the extent that such losses arise out of or are related to a
breach of the agreements or covenants hereunder of another party hereto prior to or contemporaneous
with such termination.

     3.5 Termination for Insolvency. This Agreement shall terminate without notice (a)
upon the institution by or against BSC of insolvency, receivership or bankruptcy proceedings

6

 

or any
other proceedings for the settlement of a party’s debts, which proceedings are not abandoned,
dismissed or otherwise terminated within thirty (30) calendar days after the commencement thereof,
(b) upon BSC’s making an assignment for the benefit of creditors, or (c) upon BSC’s dissolution or
ceasing to do business.

4. Miscellaneous.

     4.1 Governing Law; Consent to Jurisdiction. This Agreement shall be governed by, and
construed in accordance with the laws of the Commonwealth of Massachusetts applicable to contracts
executed in and to be performed in that state, without reference to conflict of laws principles.
EACH OF BSC AND REVA HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE COURTS
OF THE COMMONWEALTH OF MASSACHUSETTS AND TO THE JURISDICTION OF THE UNITED STATES DISTRICT COURT
FOR THE COMMON WEALTH OF MASSACHUSETTS FOR THE PURPOSE OF ANY ACTION OR PROCEEDING ARISING OUT OF
OR RELATING TO THIS AGREEMENT, AND EACH OF BSC AND REVA HEREBY IRREVOCABLY AGREES THAT ALL CLAIMS
IN RESPECT TO SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED EXCLUSIVELY IN ANY
MASSACHUSETTS STATE OR FEDERAL COURT SITTING IN THE CITY OF BOSTON. EACH OF BSC AND REVA AGREES
THAT A FINAL JUDGMENT IN ANY ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER
JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. EACH OF BSC AND REVA
IRREVOCABLY CONSENTS TO THE SERVICE OF THE SUMMONS AND COMPLAINT AND ANY OTHER PROCESS IN ANY OTHER
ACTION OR PROCEEDING RELATING TO THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, ON BEHALF OF
ITSELF OR ITS PROPERTY, BY THE PERSONAL DELIVERY OF COPIES OF SUCH PROCESS TO SUCH PARTY. NOTHING
IN THIS SECTION 4.1 SHALL AFFECT THE RIGHT OF ANY PARTY TO SERVE LEGAL PROCESS IN ANY OTHER MANNER
PERMITTED BY LAW.

     4.2 Assignability and Binding Effect. This Agreement constitutes the entire agreement
among the parties with respect to the subject matter hereof and supersedes all prior agreements and
undertakings, both written and oral, among the parties, or any of them, with respect to the subject
matter hereof. This Agreement shall not be assigned by operation of law or otherwise, except that
(a) BSC may assign all or any of its rights hereunder to any Affiliate of BSC; provided,
that no such assignment to an Affiliate shall relieve BSC of its obligations hereunder, and (b) BSC
may assign all of its rights and obligations hereunder to a person that acquires all of the capital
stock, or substantially all of the assets, of BSC or of its interventional cardiology business
unit; provided, that such person assumes BSC’s obligations under this Agreement, in
writing, and agrees to be bound by and comply with all of the terms and conditions hereof.

     4.3 Counterparts. This Agreement may be executed and delivered (including by
facsimile transmission) in one (1) or more counterparts, and by the different parties hereto in
separate counterparts, each of which when executed and delivered shall be deemed to be an
original but all of which taken together shall constitute one (1) and the same agreement.

7

 

     4.4 Titles and Subtitles. The descriptive headings contained in this Agreement are
included for convenience of reference only and shall not affect in any way the meaning or
interpretation of this Agreement. Whenever the word “include,” “includes,” or “including” appears
in this Agreement, it shall be deemed in each instance to be followed by the words “without
limitation”.

     4.5 Notices. All notices, claims and demands hereunder, and all other communications
which are required to be given in writing pursuant to this Agreement, shall be in writing and shall
be given (and shall be deemed to have been duly given upon receipt) by delivery in person or
facsimile (received at the facsimile machine to which it is transmitted prior to 5 p.m., local
time, on a business day for the party to which it is sent, or if received after 5 p.m., local time,
as of the next business day) or by registered or certified mail (postage prepaid, return receipt
requested) to the respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section 4.5):

if to BSC:

Boston Scientific Corporation

One Boston Scientific Place

Natick, Massachusetts 01760

Attention: Chief Financial Officer

Facsimile: 508-650-8956

with a copy to:

Boston Scientific Corporation

One Boston Scientific Place

Natick, Massachusetts 01760

Attention: Assistant General Counsel

Facsimile: 508-650-8956

if to Reva:

REVA Medical, Inc.

5751 Copley Drive, Suite B

San Diego, CA 92111

Attention: President

Telephone: (858) 430-0720

Facsimile: (858) 430-0729

with a copy to:

Heller Ehrman White & McAuliffe LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, CA 92122

Attention: Michael S. Kagnoff, Esq.

Telephone: (858) 450-8400

Facsimile: (825) 450-8499

8

 

     4.6 Fees and Expenses. All costs and expenses incurred in connection with this
Agreement by Reva shall be paid by Reva. All costs and expenses incurred in connection with this
Agreement by BSC shall be paid by BSC.

     4.7 Amendments and Waivers. Any term of this Agreement may be amended or waived
(either generally or in a particular instance and either retroactively or prospectively), only with
the written consent of BSC and Reva.

     4.8 Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of applicable law, or public policy, all other
conditions and provisions of this Agreement shall nevertheless remain in full force and effect so
long as the economic or legal substance of the matters referred to herein are not affected in any
manner materially adverse to any party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good
faith to modify this Agreement so as to effect the original intent of the parties as closely as
possible in a mutually acceptable manner in order that the matters referred to herein are
consummated as originally contemplated to the fullest extent possible.

     4.9 Specific Enforcement. The parties hereto agree that irreparable damage would
occur in the event that any provision of this Agreement was not performed in accordance with the
terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in
addition to any other remedy at law or equity.

[The remainder of the page is intentionally left blank.]

9

 

     IN WITNESS WHEREOF, the parties have executed this Distribution Option Agreement as an
instrument under seal as of the date first above written.

	 	 	 	 	 
	BSC:

BOSTON SCIENTIFIC CORPORATION

 	 
	By:  	/s/ Jim Gilbert
 	 
	 	Name:  	Jim Gilbert 	 
	 	Title:  	Executive Vice President and Group President, Cardiovascular 	 

	 	 	 	 	 
	REVA:

REVA MEDICAL, INC.

 	 
	By:  	/s/ Robert K. Schultz
 	 
	 	Name:  	Robert K. Schultz 	 
	 	Title:  	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]